Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2593–2616 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PLACEBO Clear all

Conditions: Knee Osteoarthritis
Interventions: inulin, Maltodextrin (Placebo); Drug
Lead sponsor: Yale University; Other
Eligibility: 40 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Diabetes Mellitus, Type 1
Interventions: OPT101; Drug
Lead sponsor: Op-T LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Walnut Creek, California • Renton, Washington

Conditions: Dry Eye Syndrome
Interventions: 0.3% BOL-303242-X ophthalmic suspension, 2% BOL-303242-X ophthalmic suspension, Placebo Comparator: Vehicle, 1% BOL-303242-X ophthalmic suspension, 2% BOL-303242-X ophthalmic suspension AM, 2% BOL-303242-X ophthalmic suspension PM; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Chemotherapy-induced Neutropenia
Interventions: EC-18, Placebo; Drug
Lead sponsor: Enzychem Lifesciences Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Hidradenitis Suppurativa
Interventions: Tulisokibart, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 16 more

Conditions: Atelectasis, Ventilation, Mechanical
Interventions: Pulmozyme (nebulized dornase alpha), Saline; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Abuse Potential
Interventions: Placebo, Alprazolam 2 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg; Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Dementia With Lewy Bodies (DLB)
Interventions: Neflamapimod; Drug
Lead sponsor: EIP Pharma Inc; Industry
Eligibility: 55 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 22
States / cities: La Jolla, California • Santa Monica, California • Aurora, Colorado + 18 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: BMS-986020, Placebo matching with BMS-986020; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 48
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 42 more

Conditions: Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions: CB-839, Cabozantinib, Placebo; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 59
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more

Conditions: Cigarette Smoking, Alcohol Consumption
Interventions: Varenicline, Placebo pill (for varenicline), Alcohol, placebo beverage (for alcohol); Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: PSORIASIS
Interventions: Etanercept, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy
Interventions: RVP-001, Placebo; Drug
Lead sponsor: Reveal Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ, Paget Disease of the Breast, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: Docosahexaenoic Acid, Placebo; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas

Conditions: Major Depressive Disorder
Interventions: Brexpiprazole, Antidepressant therapy; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Contraception
Interventions: Misoprostol, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chronic Pain
Interventions: Oxymorphone Extended Release; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 33
States / cities: Hueytown, Alabama • Phoenix, Arizona • Colorado Springs, Colorado + 27 more

Conditions: Influenza
Interventions: VXA-A1.1 Oral Vaccine, VXA Placebo Tablet; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Cypress, California

Conditions: Effect of Drug
Interventions: Aspirin 325mg; Drug
Lead sponsor: Hematology Oncology Associates of Central New York; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: East Syracuse, New York

Conditions: Antibody-mediated Rejection
Interventions: Clazakizumab, Physiologic saline solution; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 49
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 36 more

Conditions: Postoperative Pain
Interventions: Acetaminophen or Placebo; Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 90 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Spasticity, Multiple Sclerosis
Interventions: IPX056, Baclofen IR, Placebo IPX056, Placebo IR; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Tucson, Arizona • Aurora, Colorado • Tampa, Florida + 8 more

Conditions: Albuminuria
Interventions: Ramipril + Irbesartan, Ramipril + Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 55 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 11
States / cities: Tustin, California • Miami, Florida • West Palm Beach, Florida + 8 more

Conditions: Schizophrenia
Interventions: LB-102; Drug
Lead sponsor: LB Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

Inulin Supplementation for Reducing Inflammation and Knee Pain in Older Adults With Osteoarthritis

OPT101 in Type 1 Diabetes Patients

Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome

A Safety and PK Study of EC-18 in Healthy Subjects

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

Impact of Nebulized Dornase Alpha on Mechanically Ventilated Patients

An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users

Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

Effects of Varenicline in Heavy Drinking Smokers

Etanercept and Vascular Function in Psoriasis

First in Human Study of RVP-001, a New Manganese Based MRI Contrast Agent

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women

Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain

Safety Study of an Oral Vaccine to Prevent Seasonal Influenza

PFA 100 Evaluation and Reference Interval HOACNY

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Use of IV Acetaminophen in the Treatment of Post Operative Pain in Patients Undergoing Craniotomy and Spine Surgery

A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis

Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults